相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study
Simone Parisi et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naive to or switched from biologics
Tsutomu Takeuchi et al.
MODERN RHEUMATOLOGY (2022)
Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study
Dimitrios A. Pappas et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Doctor's aptitude for switching from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: experience from a single French rheumatology tertiary care center
Omar Al Tabaa et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA
Xiaomeng Yue et al.
RHEUMATOLOGY (2021)
The Prevalence of Rheumatoid Arthritis: A Systematic Review of Population-based Studies
Khalid B. Almutairi et al.
JOURNAL OF RHEUMATOLOGY (2021)
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
HoUng Kim et al.
DRUGS (2020)
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Yen-Ju Lin et al.
CELLS (2020)
The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases
Cosimo Bruni et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2020)
Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)
Marc Scherlinger et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Are There Benefits and Risks to Biosimilars from a Patient Perspective?
Jonathan Kay
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2019)
Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis - A comparison in a real-world national cohort
Catalin Codreanu et al.
BIOLOGICALS (2019)
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naive or Switching Patients: A Systematic Review
Hans C. Ebbers et al.
RHEUMATOLOGY AND THERAPY (2019)
Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
Paul Emery et al.
ADVANCES IN THERAPY (2018)
Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2016)
Epidemiology of adult rheumatoid arthritis
Y Alamanos et al.
AUTOIMMUNITY REVIEWS (2005)